Stay updated on Pembrolizumab Effects in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Effects in Solid Tumors Clinical Trial page.

Latest updates to the Pembrolizumab Effects in Solid Tumors Clinical Trial page
- Check6 days agoChange DetectedThe page now displays Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe changes are limited to the site's footer: a new Revision: v3.4.2 tag and updated/removed generic operating-status notices. There is no impact on the study details, eligibility criteria, or data presented on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check42 days agoChange DetectedA site-wide notice about a lapse in government funding has been added and the page revision updated to v3.4.1 (replacing v3.4.0).SummaryDifference0.5%

- Check48 days agoChange DetectedShow glossary has been added, and a new 'Last Update Submitted that Met QC Criteria' field is displayed. The old 'Last Update Submitted that met QC Criteria' label, casing of 'No FEAR Act data', and the page revision have been updated to v3.4.0.SummaryDifference0.2%

- Check62 days agoChange DetectedFooter shows a minor version update: Revision v3.3.4 added and v3.3.3 removed; no changes to study details, eligibility, or endpoints are apparent.SummaryDifference0.1%

- Check84 days agoChange DetectedAdded Locations: Ontario (Toronto, Princess Margaret Cancer Centre). Removed Ontario Locations header and HHS Vulnerability Disclosure; updated page revision to v3.3.3.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Effects in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Effects in Solid Tumors Clinical Trial page.